TrialThe oncologist2025

First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancer.

Ryan J Sullivan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.